Cellectar Biosciences Inc (CLRB)
3.335
+0.18
(+5.54%)
USD |
NASDAQ |
May 02, 16:00
3.335
0.00 (0.00%)
After-Hours: 16:46
Cellectar Biosciences Enterprise Value: 98.44M for May 1, 2024
Enterprise Value Chart
Historical Enterprise Value Data
Date | Value |
---|---|
May 01, 2024 | 98.44M |
April 30, 2024 | 96.18M |
April 29, 2024 | 96.50M |
April 26, 2024 | 94.24M |
April 25, 2024 | 93.92M |
April 24, 2024 | 95.21M |
April 23, 2024 | 96.82M |
April 22, 2024 | 99.41M |
April 19, 2024 | 94.24M |
April 18, 2024 | 94.57M |
April 17, 2024 | 100.05M |
April 16, 2024 | 103.28M |
April 15, 2024 | 103.60M |
April 12, 2024 | 109.73M |
April 11, 2024 | 116.18M |
April 10, 2024 | 109.08M |
April 09, 2024 | 116.83M |
April 08, 2024 | 119.41M |
April 05, 2024 | 117.79M |
April 04, 2024 | 116.50M |
April 03, 2024 | 124.89M |
April 02, 2024 | 125.21M |
April 01, 2024 | 122.96M |
March 28, 2024 | 124.89M |
March 27, 2024 | 113.76M |
Date | Value |
---|---|
March 26, 2024 | 120.70M |
March 25, 2024 | 121.34M |
March 22, 2024 | 127.15M |
March 21, 2024 | 121.34M |
March 20, 2024 | 73.87M |
March 19, 2024 | 74.91M |
March 18, 2024 | 65.99M |
March 15, 2024 | 68.68M |
March 14, 2024 | 66.61M |
March 13, 2024 | 69.93M |
March 12, 2024 | 71.80M |
March 11, 2024 | 74.70M |
March 08, 2024 | 79.47M |
March 07, 2024 | 80.92M |
March 06, 2024 | 79.47M |
March 05, 2024 | 80.51M |
March 04, 2024 | 84.45M |
March 01, 2024 | 83.62M |
February 29, 2024 | 77.81M |
February 28, 2024 | 78.23M |
February 27, 2024 | 76.98M |
February 26, 2024 | 68.89M |
February 23, 2024 | 65.78M |
February 22, 2024 | 65.99M |
February 21, 2024 | 64.43M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-7.867M
Minimum
May 12 2022
127.15M
Maximum
Mar 22 2024
17.34M
Average
10.04M
Median
Oct 10 2023
Enterprise Value Benchmarks
Perspective Therapeutics Inc | 990.24M |
Eli Lilly and Co | 761.94B |
Actinium Pharmaceuticals Inc | 147.66M |
Bristol-Myers Squibb Co | 135.68B |
Altimmune Inc | 303.41M |
Enterprise Value Related Metrics
Net Income (Quarterly) | -7.449M |
Total Expenses (Quarterly) | 12.55M |
EPS Diluted (Quarterly) | -0.40 |
Earnings Yield | -92.95% |